AstraZeneca's Breast Cancer Pill Falls Short in Late-Stage Trial

AstraZeneca (AZN) suffered a clinical setback when its breast cancer pill camizestrant, sold as Etcamah, failed to achieve a statistically significant improvement in progression-free survival in a late-stage trial — just one week after the drug received US regulatory approval.

The drug, tested in combination with Pfizer's (PFE) cancer treatment Ibrance, showed only a numerical improvement in the primary endpoint among previously untreated patients with a common form of advanced breast cancer. AstraZeneca's US-listed shares fell three per cent in after-hours trading following the announcement.

Analysts were largely sanguine. Trung Huynh of RBC Capital described the result as a "manageable setback" that clears a near-term uncertainty for investors without fundamentally altering the long-term investment case for the drug. James Gordon of Barclays called the update "well anticipated by the market," noting the prior failure of a comparable combination from Roche (RHHBY) and cautious signals from AstraZeneca itself ahead of the readout.

In March, Roche's analogous drug pairing had similarly failed to significantly slow disease progression in newly diagnosed patients, tempering expectations across the class.

The SERENA-6 trial enrolled 1,371 patients with hormone receptor-positive, HER2-low advanced breast cancer — the most prevalent subtype, in which hormones such as estrogen drive tumor growth. The Etcamah-Ibrance combination was compared against Ibrance alongside hormone-suppressing agents.

Despite the trial miss, the commercial case for camizestrant remains intact in a narrower patient segment. Last week, the US Food and Drug Administration granted accelerated approval to the Etcamah combination for patients whose tumors carry the ESR1 mutation, a resistance mechanism that emerges in later-line settings. Jefferies estimates peak annual sales potential of more than $5 billion for the drug, with the majority of that opportunity residing in the early breast cancer setting.

AstraZeneca said full trial data would be presented at a forthcoming medical conference.